Vonoprazan
VPED-103
Phase 1 small_molecule completed
Quick answer
Vonoprazan for Gastroesophageal Reflux Disease is a Phase 1 program (small_molecule) at Phathom Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Phathom Pharmaceuticals
- Indication
- Gastroesophageal Reflux Disease
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed